Valuation: Scholar Rock Holding Corporation

Market Cap 5.79B 5.07B 4.71B 4.33B 8.15B 558B 8.27B 56.08B 21.95B 273B 21.73B 21.26B 944B P/E 2026 *
-15.2x
P/E 2027 * -18.9x
Enterprise Value 5.49B 4.81B 4.46B 4.1B 7.73B 529B 7.84B 53.16B 20.81B 259B 20.59B 20.15B 895B EV / Sales 2026 *
842x
EV / Sales 2027 * 36.3x
Free-Float
99.22%
Yield 2026 *
-
Yield 2027 * -
1 day-5.07%
1 week-10.62%
Current month-12.18%
1 month-1.81%
3 months+2.05%
6 months+1.13%
Current year+9.65%
1 week 47.28
Extreme 47.275
53.33
1 month 47.28
Extreme 47.275
58.49
Current year 38.75
Extreme 38.75
58.49
1 year 27.07
Extreme 27.07
58.49
3 years 5.93
Extreme 5.93
58.49
5 years 4.32
Extreme 4.325
58.49
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Tech/Sci/R&D Officer 51 2022-08-31
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Director

-2,544 0.0022%
7/1/26 Sell

Director

-3,053 0.0027%
7/1/26
ARCH Venture Partners LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-5.07%-10.62%+20.81%+586.08% 6.1B
-0.43%-4.26%+52.09%+85.69% 55.57B
-0.24%+1.04%+55.76%+54.21% 54.26B
-1.82%-2.89%+3.61%+405.88% 23.54B
-0.54%-0.17%-17.60%-15.43% 23.35B
+0.57%-0.66%+35.86%-3.67% 20.32B
+3.16%+0.79%+37.98%-31.36% 17.36B
+0.10%-0.96%+38.00%+548.50% 15.59B
+0.43%-10.61%+175.63%+299.61% 14.96B
-2.03%-1.03%+23.63%+179.23% 14.11B
Average -0.59%-1.70%+42.58%+210.87% 24.51B
Weighted average by Cap. -0.32%-0.70%+43.49%+144.46%

Financials

2026 *2027 *
Net sales 6.51M 5.71M 5.3M 4.87M 9.17M 628M 9.31M 63.1M 24.7M 307M 24.44M 23.92M 1.06B 149M 131M 122M 112M 211M 14.42B 214M 1.45B 567M 7.06B 561M 549M 24.38B
Net income -410M -359M -333M -306M -577M -39.53B -586M -3.97B -1.55B -19.34B -1.54B -1.5B -66.82B -356M -312M -290M -266M -502M -34.38B -509M -3.45B -1.35B -16.82B -1.34B -1.31B -58.12B
Net Debt -302M -265M -246M -226M -425M -29.15B -432M -2.93B -1.15B -14.26B -1.13B -1.11B -49.27B -356M -312M -289M -266M -501M -34.31B -508M -3.45B -1.35B -16.79B -1.33B -1.31B -58B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-07-22 US$48.30 -5.07% 1,607,919
26-07-21 US$50.88 +0.43% 824,450
26-07-20 US$50.66 -4.16% 898,227
26-07-17 US$52.86 +2.18% 811,945
26-07-16 US$51.73 -4.27% 1,052,481
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.30USD
Average target price
59.31USD
Spread / Average Target
+22.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock